Endothelial dysfunction in systemic sclerosis

Current Opinion in Rheumatology

Volumn 26, Issue 6, 2014, Pages 615-620

  Altorok, Nezam ^a   Wang, Yongqing ^a   Kahaleh, Bashar ^a  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

Author keywords

Endothelial dysfunction; Microvascular endothelial cells; Scleroderma; Systemic sclerosis; Vasculopathy

Indexed keywords

AUTOANTIBODY; CELL ADHESION MOLECULE; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; ENDOTHELIAL CELL ANTIBODY;

ANGIOGENESIS; CAPILLARY ENDOTHELIAL CELL; ENDOTHELIAL DYSFUNCTION; EPIGENETICS; FIBROBLAST; HUMAN; IMMUNE SYSTEM; INTERMITTENT HYPOXIA; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; ENDOTHELIUM CELL; METABOLISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION;

EID: 84927773004     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000112     Document Type: Review

References (57)

1. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005; 26:587-595.
2. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013; 65:1953-1962.
3. An extensive review of the vascular disease in scleroderma with detailed description of all facets of vascular involvement in the disease.
4. Romero LI, Zhang DN, Cooke JP, et al. Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma. Vasc Med 2000; 5:147-158.
5. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48:489-509.
6. Yamane K, Kashiwagi H, Suzuki N, et al. Elevated plasma levels of endothelin-1 in systemic sclerosis. Arthritis Rheum 1991; 34:243-244.
7. Renaudineau Y, Revelen R, Levy Y, et al. Antiendothelial cell antibodies in systemic sclerosis. Clin Diagn Lab Immunol 1999; 6:156-160.
8. Sgonc R, Gruschwitz MS, Boeck G, et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000; 43:2550-2562.
9. Worda M, Sgonc R, Dietrich H, et al. In vivo analysis of the apoptosis-inducing effect of antiendothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum 2003; 48:2605-2614.
10. Zimmer S, Steinmetz M, Asdonk T, et al. Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ Res 2011; 108:1358-1366.
11. Bulkley GB. Physiology of reactive oxidant-mediated signal transduction: an overview. Biochem Soc Trans 1997; 25:804-812.
12. Makarenko VV, Usatyuk PV, Yuan G, et al. Intermittent hypoxia-induced endothelial barrier dysfunction requires ROS-dependent MAP kinase activation. Am J Physiol Cell Physiol 2014; 306:C745-C752.
13. Altorok N, Almeshal N, Wang Y, Kahaleh B. Epigenetics, the holy grail in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2014; doi: 10.1093/rheumatology/keu155. [Epub ahead of print]
14. Nasim MT, Ogo T, Chowdhury HM, et al. BMPR-II deficiency elicits proproliferative and antiapoptotic responses through the activation of TGFbeta-TAK1-MAPK pathways in PAH. Hum Mol Genet 2012; 21:2548-2558.
15. Wang Y, Kahaleh B. Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma. J Cell Mol Med 2013; 17:1291-1299.
16. Star GP, Giovinazzo M, Langleben D. Effects of bone morphogenic proteins and transforming growth factor-beta on in-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells. Vascul Pharmacol 2009; 50:45-50.
17. Wang YK, Kahaly OR, Kahaleh B. Down-regulated MicroRNA-152 induces aberrant DNA methylation in scleroderma endothelial cells by targeting DNA methyltransferase 1. Arthritis Rheum 2010; 62:1352.
18. Wang Y, Kahaleh B. Epigenetic regulation in scleroderma: high-throughput Dna methylation profiling of Ssc fibroblasts and microvascular endothelial cells and the central role for Nos3 and Fli1 epigenetic repression in the emergence of Ssc cellular phenotype [abstract]. American College of Rheumatology; Annual scientific meeting 2007.
19. Distler JH, Gay S, Distler O. Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 2006; 45 (Suppl 3):iii26-iii27.
20. Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002; 4:R11.
21. Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004; 95:109-116.
22. D'Alessio S, Fibbi G, Cinelli M, et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004; 50:3275-3285.
23. Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M. Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant. Trends Cardiovasc Med 2011; 21:204-210.
24. Manetti M, Guiducci S, Romano E, et al. Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis. Ann Rheum Dis 2013; 72:1425-1427.
25. Distler JH, Wenger RH, Gassmann M, et al. Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2004; 50:10-23.
26. Ioannou M, Pyrpasopoulou A, Simos G, et al. Upregulation of VEGF expression is associated with accumulation of HIF-1alpha in the skin of naive scleroderma patients. Mod Rheum 2013; 23:1245-1248.
27. Derrett-Smith EC, Dooley A, Gilbane AJ, et al. Endothelial injury in a transforming growth factor beta-dependent mouse model of scleroderma induces pulmonary arterial hypertension. Arthritis Rheum 2013; 65:2928-2939.
28. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54:2271-2279.
29. Noda S, Asano Y, Takahashi T, et al. Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis. Rheumatology (Oxford) 2013; 52:790-799.
30. van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014; 370:433-443.
31. Ichimura Y, Asano Y, Akamata K, et al. Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis. Arch Dermatol Res 2014; 306:331-338.
32. Giusti B, Fibbi G, Margheri F, et al. A model of antiangiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 2006; 8:R115.
33. Giusti B, Margheri F, Rossi L, et al. Desmoglein-2-integrin Beta-8 interaction regulates actin assembly in endothelial cells: deregulation in systemic sclerosis. PloS One 2013; 8:e68117.
34. Manetti M, Guiducci S, Romano E, et al. Differential expression of junctional adhesion molecules in different stages of systemic sclerosis. Arthritis Rheum 2013; 65:247-257.
35. Arends SJ, Damoiseaux JG, Duijvestijn AM, et al. Functional implications of IgG antiendothelial cell antibodies in pulmonary arterial hypertension. Autoimmunity 2013; 46:463-470.
36. Wolf SI, Howat S, Abraham DJ, et al. Agonistic anti-ICAM-1 antibodies in scleroderma: activation of endothelial pro-inflammatory cascades. Vascul Pharmacol 2013; 59:19-26.
37. Serratì S, Chilla A, Laurenzana A, et al. Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)/transforming growth factor beta-dependent mesenchymal-to-mesenchymal transition. Arthritis Rheum 2013; 65:258-269.
38. Kuwana M, Okazaki Y. Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct comparison of protocols. Ann Rheum Dis 2012; 71:617-620.
39. Del Papa N, Quirici N, Scavullo C, et al. Antiendothelial cell antibodies induce apoptosis of bone marrow endothelial progenitors in systemic sclerosis. J Rheumatol 2010; 37:2053-2063.
40. Kuwana M, Okazaki Y. Brief report: impaired in vivo neovascularization capacity of endothelial progenitor cells in patients with systemic sclerosis. Arthritis Rheumatol 2014; 66:1300-1305.
41. Poredos P, Jezovnik MK. Testing endothelial function and its clinical relevance. J Atheroscler Thromb 2013; 20:1-8.
42. Szucs G, Timar O, Szekanecz Z, et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis: relevance for prevention of vascular complications. Rheumatology (Oxford) 2007; 46:759-762.
43. Le JH, Cho KI. Association between endothelial function and microvascular changes in patients with secondary Raynaud's phenomenon. Clin Rheumatol 2014; 2014:1-7.
44. Della Rossa A, Cazzato M, d'Ascanio A, et al. Alteration of microcirculation is a hallmark of very early systemic sclerosis patients: a laser speckle contrast analysis. Clin Exp Rheumatol 2013; 31 (2 Suppl 76):109-114.
45. Rosato E, Barbano B, Gigante A, et al. Doppler ultrasound study of penis in men with systemic sclerosis: a correlation with Doppler indices of renal and digital arteries. Int J Immunopathol Pharmacol 2013; 26:1007-1011.
46. Pandey JP, LeRoy EC. Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum 1998; 41:10-15.
47. Waldman WJ, Knight DA, Adams PW. Cytolytic activity against allogeneic human endothelia: resistance of cytomegalovirus-infected cells and virally activated lysis of uninfected cells. Transplantation 1998; 66:67-77.
48. Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188:1359-1368.
49. Mold C, Morris CA. Complement activation by apoptotic endothelial cells following hypoxia/reoxygenation. Immunology 2001; 102:359-364.
50. Barnes TC, Spiller DG, Anderson ME, et al. Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis? Ann Rheum Dis 2011; 70:366-372.
51. Ali MH, Schlidt SA, Chandel NS, et al. Endothelial permeability and IL-6 production during hypoxia: role of ROS in signal transduction. Am J Physiol 1999; 277 (5 Pt 1):L1057-L1065.
52. Qi H, Wang P, Liu C, et al. Involvement of HIF-1alpha in MLCK-dependent endothelial barrier dysfunction in hypoxia. Cell Physiol Biochem 2011; 27:251-262.
53. Asano Y, Stawski L, Hant F, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010; 176:1983-1998.
54. Dimitroulas T, Sandoo A, Kitas GD. Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. Int J Mol Sci 2012; 13:12315-12335.
55. Dooley A, Gao B, Bradley N, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) 2006; 45:676-684.
56. Tabata H, Yamakage A, Yamazaki S. Cutaneous localization of endothelin-1 in patients with systemic sclerosis: immunoelectron microscopic study. Int J Dermatol 1997; 36:272-275.
57. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991; 34:978-983.